Equities Analysts Issue Forecasts for CGTX FY2025 Earnings

Cognition Therapeutics, Inc. (NASDAQ:CGTX) – Stock analysts at Chardan Capital issued their FY2025 earnings per share (EPS) estimates for shares of Cognition Therapeutics in a report issued on Monday, March 24th. Chardan Capital analyst D. Gataulin forecasts that the company will post earnings per share of ($0.32) for the year. Chardan Capital has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Cognition Therapeutics’ current full-year earnings is ($0.80) per share. Chardan Capital also issued estimates for Cognition Therapeutics’ FY2026 earnings at ($0.15) EPS.

A number of other research firms have also recently commented on CGTX. HC Wainwright cut their price target on shares of Cognition Therapeutics from $6.00 to $5.00 and set a “buy” rating on the stock in a report on Monday. B. Riley upgraded Cognition Therapeutics from a “neutral” rating to a “buy” rating and increased their target price for the company from $1.00 to $1.50 in a research note on Thursday, December 19th. Finally, Brookline Capital Management raised Cognition Therapeutics to a “strong-buy” rating in a report on Monday, January 27th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Cognition Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $7.50.

Cognition Therapeutics Stock Performance

NASDAQ:CGTX opened at $0.44 on Thursday. The firm has a market cap of $18.35 million, a P/E ratio of -0.46 and a beta of 1.03. Cognition Therapeutics has a fifty-two week low of $0.34 and a fifty-two week high of $2.95. The firm has a 50-day simple moving average of $0.57 and a two-hundred day simple moving average of $0.55.

Cognition Therapeutics (NASDAQ:CGTX) last issued its quarterly earnings results on Thursday, March 20th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.01). During the same quarter in the previous year, the company posted ($0.27) earnings per share.

Institutional Investors Weigh In On Cognition Therapeutics

A number of large investors have recently added to or reduced their stakes in CGTX. SG Americas Securities LLC purchased a new position in shares of Cognition Therapeutics in the 4th quarter worth $26,000. Virtu Financial LLC bought a new position in Cognition Therapeutics in the third quarter valued at about $27,000. Sigma Planning Corp boosted its position in Cognition Therapeutics by 211.6% in the fourth quarter. Sigma Planning Corp now owns 614,490 shares of the company’s stock worth $431,000 after purchasing an additional 417,300 shares during the last quarter. BIOS Capital Management LP bought a new stake in shares of Cognition Therapeutics during the 4th quarter valued at about $4,208,000. Finally, Two Sigma Investments LP increased its position in shares of Cognition Therapeutics by 372.2% during the 4th quarter. Two Sigma Investments LP now owns 53,691 shares of the company’s stock valued at $38,000 after purchasing an additional 42,321 shares during the last quarter. Institutional investors own 43.35% of the company’s stock.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.